Candidate: STI-6991 to prevent SARS-CoV-2 infection

Category: VAX

Type: I-CellTM COVID-19 “decoy” cellular vaccine made of replication-deficient human erythroleukemia K562 immune-training cells expressing membrane-bound S1 protein of the SARS-CoV-2 virus.

Status: Sorrento said March 25 it was developing STI-6991, and was in active discussions with the FDA’s Center for Biologics Evaluation and Research under IND#019724 concerning IND-enabling studies, CMC (chemistry, manufacturing and controls), clinical protocol and end-points for potential accelerated approval. Sorrento said intends to submit a full package for an IND filing that would enable human clinical trials to start “as soon as possible.”

Sorrento expects to use a replicating cell line (human erythroleukemia, K562) to incorporate SARS-CoV-2’s spike protein or its S1 domain onto the cellular membrane so that the viral antigen is presented on a decoy cell surface to elicit both T cell and B cell immunities.

Late last month, Sorrento said it entered into a research testing agreement with The University of Texas Medical Branch at Galveston for preclinical testing of Sorrento’s COVID-19 therapeutic product candidates.


COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:

● ANTIVIRAL
● VAX
● ANTIBODY
● RNA